Results for Sickle Cell Anemia

Dr. Chou focuses on regenerative blood cellular therapy, the mechanisms of normal human hematopoietic development, and the pathophysiology of pediatric hematologic diseases.

Dr. Hartung is the interim director of CHOP's Sickle Cell Center and the director of innovation of the CuRED Frontier Program. His clinical focus is on bone marrow failure syndromes and sickle cell disease and his research focus is on entrepreneurial science and medical device development.

Dr. Rivella is an expert in the pathophysiology of erythroid and iron disorders and in the generation of lentiviral vectors for the cure of hemoglobinopathies. He also investigates additional disorders such as anemia of inflammation and hemochromatosis.

Dr. Olson aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes. He conducts clinical trials of HSCT for non-malignant hematologic diseases. His laboratory explores both basic and translational research focused on genomics of BMF and the impact of BMF on hematopoietic niche function during HSCT.

Dr. Guerra is researching innovating therapies to treat β-thalassemia and sickle cell anemia and use lentiviruses as a tool. Her work aims to discover new biological targets that can be used to treat β-thalassemia and other forms of anemia.

Dr. Castracani’s research work is focused on the most common form of X-linked sideroblastic anemia which results from mutations in the ALAS2 gene and inhibits normal heme biosynthesis.